Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mauricio Emmanuel Burotto Pichun"'
Autor:
Arun Rajan, Raffit Hassan, Julia Wilkerson, Mauricio Emmanuel Burotto Pichun, Giuseppe Giaccone, Anish Thomas, Antonio Tito Fojo
Publikováno v:
Journal of Clinical Oncology. 33:e18564-e18564
e18564 Background: TETs are rare tumors with limited treatment options that exhibit a wide range of growth characteristics. Standard measures of evaluating tumor response to investigational agents ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba36b6814ad1a40509b0d3174eafad5f
https://doi.org/10.1200/jco.2015.33.15_suppl.e18564
https://doi.org/10.1200/jco.2015.33.15_suppl.e18564
Autor:
Rodrigo Andres Ascui, Carlos del Valle Rojas, Humberto Cerda, Mauricio Emmanuel Burotto Pichun, Patricia Banchero, Ricardo Silva, Mauricio Reyes, Jorge M Arancibia, Osvaldo Rudy Aren
Publikováno v:
Journal of Clinical Oncology. 33:8075-8075
8075 Background: The recommended dose for erlotinib of 150 mg was developed based on the maximum tolerated dose (MTD); meanwhile the suggested dose for gefitinib is only one third of its MTD. Studi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d22456879b2d57a7122a135669c9b7e
https://doi.org/10.1200/jco.2015.33.15_suppl.8075
https://doi.org/10.1200/jco.2015.33.15_suppl.8075
Autor:
Christine Bryla, Sanjeeve Balasubramaniam, Laleh Amiri-Kordestani, Nicholas J. Patronas, Mauricio Emmanuel Burotto Pichun, Esther Mena Gonzalez, Peter L. Choyke, Maria Liza Lindenberg, Tito Fojo, Susan E. Bates
Publikováno v:
Journal of Clinical Oncology. 33:2552-2552
2552 Background: ANG1005 is a novel drug conjugate consisting of 3 molecules of paclitaxel covalently linked to Angiopep-2, designed to cross the blood brain barrier (BBB) via endocytosis after bin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2834072a61bf908c684d31e15d5ed0ac
https://doi.org/10.1200/jco.2015.33.15_suppl.2552
https://doi.org/10.1200/jco.2015.33.15_suppl.2552
Autor:
Mauricio Emmanuel Burotto Pichun, Margarita Velarde, Susan E. Bates, Roland Daerr, Tito Fojo, Maureen Edgerly, Karen T. Adams, Karel Pacak
Publikováno v:
Journal of Clinical Oncology. 33:457-457
457 Background: Malignant pheochromocytoma/paraganglioma (P/PG) is a rare malignancy. Management of metastatic disease includes surgery, external radiation, 131I-MIBG and systemic chemotherapy. CVD (cyclophosphamide, vincristine and dacarbazine) is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beb1658fb545513d878584d5437f9c1e
https://doi.org/10.1200/jco.2015.33.7_suppl.457
https://doi.org/10.1200/jco.2015.33.7_suppl.457
Autor:
Julia Wilkerson, Mauricio Emmanuel Burotto Pichun, Irfan Jawed, Antonio Tito Fojo, Austin G. Duffy
Publikováno v:
Journal of Clinical Oncology. 32:3642-3642
3642 Background: The past two decades have seen steady gains in the overall survival (OS) of colorectal cancer (CRC) patients. Methods: We reviewed 106 phase III and large phase II trials in CRC ev...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eaff8e1a3784521a44ceff64f182cd7
https://doi.org/10.1200/jco.2014.32.15_suppl.3642
https://doi.org/10.1200/jco.2014.32.15_suppl.3642
Autor:
Julia Wilkerson, Herbert L. Kotz, Margarita Velarde, Maureen Edgerly, Sanjeeve Bala, Antonio Tito Fojo, Susan E. Bates, Mauricio Emmanuel Burotto Pichun
Publikováno v:
Journal of Clinical Oncology. 32:5593-5593
5593 Background: Ixabepilone is a microtubule-stabilizing agent approved for metastatic breast cancer. Preclinical data indicates activity in taxane-sensitive and resistant cells. Metastatic cervic...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f34b84bf6cc0344526583e05522649
https://doi.org/10.1200/jco.2014.32.15_suppl.5593
https://doi.org/10.1200/jco.2014.32.15_suppl.5593
Autor:
Nicolas Acquavella, Maureen Edgerly, Antonio Tito Fojo, Sanjeeve Balasubramaniam, Susan E. Bates, Mauricio Emmanuel Burotto Pichun
Publikováno v:
Journal of Clinical Oncology. 32:427-427
427 Background: Metastatic renal cell carcinoma (mRCC) remains incurable. Seven targeted agents are approved for mRCC, five targeting VEGFR and two m-TOR inhibitors. Most approvals have been based on improvements in progression free survival (PFS). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63c68f3c97b708db1d00c38801369d63
https://doi.org/10.1200/jco.2014.32.4_suppl.427
https://doi.org/10.1200/jco.2014.32.4_suppl.427
Autor:
Antonio Tito Fojo, Edward Espinal Dominguez, Mauricio Emmanuel Burotto Pichun, Julia Wilkerson, Krastan B. Blagoev, Montserrat Blanco-Codesido, Pilar Garcia-Alfonso
Publikováno v:
Journal of Clinical Oncology. 31:e14592-e14592
e14592 Background: Multiple analyses have concluded anti-EGFR antibodies are detrimental to a majority of patients (pts) whose CRCs harbor mutant KRAS. While panitumumab may benefit some pts with tumors harboring WT KRAS, in the majority the added be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b058dd204b19e21b49ea203ced8fe96
https://doi.org/10.1200/jco.2013.31.15_suppl.e14592
https://doi.org/10.1200/jco.2013.31.15_suppl.e14592
Autor:
Mauricio Emmanuel Burotto Pichun, Wilfred D. Stein, Julia Wilkerson, Robert J. Motzer, Tito Fojo, Susan E. Bates
Publikováno v:
Journal of Clinical Oncology. 31:4585-4585
4585 Background: In the last seven years the FDA and the EMA have approved seven agents for treatment of RCC. Five of these target the VEGF pathway. Methods: We conducted a detailed analysis of data from the sunitinib registration trial examining the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::980bfdaa8d02df6e9e42dba12d258121
https://doi.org/10.1200/jco.2013.31.15_suppl.4585
https://doi.org/10.1200/jco.2013.31.15_suppl.4585